Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Assets (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Non-Current Assets for 6 consecutive years, with $79.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 28.9% to $79.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $382.7 million through Dec 2025, down 35.65% year-over-year, with the annual reading at $79.1 million for FY2025, 28.9% down from the prior year.
  • Non-Current Assets hit $79.1 million in Q4 2025 for Lyell Immunopharma, down from $79.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $567.2 million in Q3 2021 to a low of $79.1 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $249.2 million across 5 years, with a median of $208.1 million in 2023.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 72.36% in 2021 and later plummeted 52.85% in 2025.
  • Year by year, Non-Current Assets stood at $501.1 million in 2021, then tumbled by 42.87% to $286.3 million in 2022, then tumbled by 31.76% to $195.3 million in 2023, then tumbled by 43.04% to $111.3 million in 2024, then dropped by 28.9% to $79.1 million in 2025.
  • Business Quant data shows Non-Current Assets for LYEL at $79.1 million in Q4 2025, $79.8 million in Q3 2025, and $103.2 million in Q2 2025.